Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, V...
Ocean Biomedical, Inc. (OCEA)
Company Research
Source: Yahoo! Finance
of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 - 8. The late breaker Phase 1b data presented today, (for more information, go to VirionTx.com ), which includes Virion's first checkpoint modifier, glycoprotein D (gD), demonstrated that VRON-0200 was not only safe and well tolerated, but immunogenic in the majority of chronically HBV-infected patients, following a single intramuscular injection. “Chronic HBV infection severely impairs a patient's ability to clear the virus. A single low dose injection of VRON-0200 was able to stimulate T cell
Show less
Read more
Impact Snapshot
Event Time:
OCEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCEA alerts
High impacting Ocean Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
OCEA
News
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024GlobeNewswire
- Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QGlobeNewswire
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease [Yahoo! Finance]Yahoo! Finance
OCEA
Sec Filings
- 5/30/24 - Form 8-K
- 5/14/24 - Form NT
- 4/24/24 - Form 8-K
- OCEA's page on the SEC website